---
title: "Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings"
description: "Daiwa has downgraded Pfizer (PFE) to a neutral rating after the company's Q4 2025 earnings report, which showed $17.6 billion in revenue and $0.66 EPS, exceeding expectations. Bernstein, however, main"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275968662.md"
published_at: "2026-02-14T06:55:16.000Z"
---

# Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings

> Daiwa has downgraded Pfizer (PFE) to a neutral rating after the company's Q4 2025 earnings report, which showed $17.6 billion in revenue and $0.66 EPS, exceeding expectations. Bernstein, however, maintained its Market Perform rating and $30 price target for Pfizer, highlighting it as a promising low-cost stock to buy.

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS \[…\]

### Related Stocks

- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [TBXU.US - Direxion Daily Biotech Top 5 Bull 2X ETF](https://longbridge.com/en/quote/TBXU.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Basilea Pharmaceutica erhält Meilensteinzahlung für Cresemba-Verkäufe in Asien und China | Basilea Pharmaceutica AG announced a milestone payment of $5 million triggered by strong sales of its antifungal drug Cr | [Link](https://longbridge.com/en/news/275271671.md) |
| 07:59 ETPfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator | BaseLaunch has announced that Pfizer is the newest partner in its biotech venture incubator, increasing the total number | [Link](https://longbridge.com/en/news/275461886.md) |
| Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund | Pfizer has agreed to accept $29 million to settle a dispute with the SEC related to an insider trading case involving St | [Link](https://longbridge.com/en/news/275506783.md) |
| Basilea to Receive $5 Million Milestone Payment from Pfizer for Antifungal Drug | Basilea to Receive $5 Million Milestone Payment from Pfizer for Antifungal Drug | [Link](https://longbridge.com/en/news/275275339.md) |
| Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile | Valneva's IXCHIQ chikungunya vaccine faces new UK restrictions for individuals over 60 and those with specific health co | [Link](https://longbridge.com/en/news/275930832.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.